Hata Yujiro S 4

What Happened
Yujiro Hata, President, CEO and a director of IDEAYA Biosciences (IDYA), was granted a derivative award to acquire 600,000 shares on January 30, 2026. The Form 4 reports an acquisition price of $0.00 and classifies the grant as a derivative (option) subject to vesting. This is a compensation award rather than an open‑market purchase or sale.

Key Details

• Transaction date: 2026-01-30; Form 4 filed: 2026-02-02 (filing appears timely).
• Amount: 600,000 shares (derivative award); reported acquisition price $0.00.
• Shares owned after transaction: not specified in the filing.
• Footnote (vesting): 25% of the shares vest on the first anniversary measured from January 1, 2026 (the Vesting Commencement Date), then 1/48th of the total shares vest each month thereafter, with full vesting on the fourth anniversary.
• Filing code: A (grant/award). No 10b5-1, cashless exercise, tax‑withholding, or late‑filing flags noted on the filing.

Context
This is a time‑based derivative grant (described in the footnote as an option) that vests over four years, so the shares are not immediately available for sale. Such grants are common executive compensation and do not by themselves indicate immediate insider buying or selling activity. For investors, the key takeaways are the size of the award (600k shares) and the multi‑year vesting schedule that links potential insider holdings to long‑term company performance.